Tempus Announces 18 Abstracts Accepted For Presentation at the American Association for Cancer Research Annual Meeting 2024
Tempus, a leader in artificial intelligence and precision medicine, today announced 18 abstracts were accepted for presentation at the 2024 American Association for Cancer Research (AACR) Annual Meeting, which convenes from April 5-10, in San Diego, California. Tempus researchers will demonstrate how the company's AI-enabled precision medicine platform collects and analyzes high-quality, multimodal datasets to advance cancer research.
"We look forward to presenting 18 abstracts at AACR this year, demonstrating the breadth and depth of our research both at Tempus and with our biopharma collaborators," said Ezra Cohen, MD, Chief Medical Officer, Oncology at Tempus. "Our research showcases the power of combining our molecular profiling offerings with our multimodal database to better understand cancer biology, treatment response, and patient outcomes."
Session Date & Time: Monday, April 8, 2024; 1:30 p.m. - 5:00 p.m. PT
Location: Poster Section 41
Overview: Tempus xM used for treatment response monitoring (TRM) is an algorithm that quantifies changes in circulating DNA tumor fraction (TF) and can be simultaneously used to detect the emergence of ESR1 mutation (ESR1m) variants. In a heterogeneous real-world cohort of ER+ HER2- metastatic breast cancer patients, we showed that the combined effect of molecular response and ESR1 mutation status, a mutation associated with resistance to aromatase inhibitors (AIs), was associated with real-world overall survival outcomes. These preliminary findings suggest that xM used for TRM can identify patients with ESR1m and poor response on AI who may benefit from switching therapy.
Session Date & Time: Monday, April 8, 2024; 9:00 a.m. - 12:30 p.m. PT
Location: Poster Section 37
Overview: To more efficiently filter out clonal hematopoiesis (CH) variants from tumor-derived variants, the team trained a random forest classifier on advanced, pan-solid tumor cancer samples sequenced using liquid biopsy and solid-tumor NGS with matched buffy coat assays (n=660). On a held-out validation set of samples (n=661), the classifier could reliably distinguish between CH and other tumor-derived variants with high accuracy, sensitivity, and specificity using only liquid biopsy data for predictions, providing an operationally simpler alternative to combined liquid and solid-based methodologies.
Session Date & Time: Tuesday, April 9, 2024; 9:00 a.m. - 12:30 p.m. PT
Location: Poster Section 44
Overview: By analyzing changes in circulating DNA tumor fraction (ctDNA TF) in a real-world pan-cancer cohort of patients treated with Tyrosine kinase inhibitors (TKIs), the research team found that patients classified as molecular responders (defined as ? 50% in ctDNA tumor fraction) had significantly improved real-world overall survival and progression-free survival compared to molecular non-responders. Based on these findings, xM used for TRM may be used to optimize treatment decision making for patients treated with TKIs, sparing patients who do not respond to TKIs from ineffective therapy.
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world's largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.
Tachyus announced a new contract today with Grayson Mill Energy (GME) for Aurion, its cloud-scalable, integrated GHG emissions management platform. Using Aurion, GME will be able to evaluate the impact of future operational plans, like field...
Nektar Therapeutics will announce its financial results for the first quarter 2024 on Thursday, May 9, 2024, after the close of U.S.-based financial markets. Howard Robin, President and Chief Executive Officer, will host a conference call to review...
Pye-Barker Fire & Safety ? the largest fully integrated and full-service fire protection, life safety and security services provider in the United States ? has acquired ADS Systems with the goal of providing security and fire alarm solutions to more...
UpGuard, esteemed for its innovative Third-Party and Supplier Risk Management solutions and ranked #1 by G2 for seven consecutive quarters, was recognized today as one of the Australian Financial Review BOSS's Best Places to Work in Technology. This...
Genpact Limited , a global professional services and solutions firm delivering outcomes that shape the future, today announced that its board of directors has declared a cash dividend of $0.1525 per common share for the second quarter of 2024. The...